Related Experiment Video
Updated: Jul 27, 2026
Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
Published on: November 7, 2018
Risks associated with hepatitis A and hepatitis B in patients with hepatitis C
1University of Massachusetts Memorial Medical Center, 55 Lake Avenue North, Worcester, MA 01655, USA. koffr@ummhc.org
Insights
Hepatitis C virus (HCV) patients should receive hepatitis A virus (HAV) and hepatitis B virus (HBV) vaccinations to prevent severe liver disease. Early vaccination is crucial for optimal immune response in individuals with chronic liver conditions.
Area of Science:
- Hepatology
- Vaccinology
- Infectious Diseases
Background:
- Individuals with Hepatitis C Virus (HCV) share risk factors for Hepatitis A Virus (HAV) and Hepatitis B Virus (HBV) infection.
- Superinfection with HAV or HBV can lead to severe hepatitis, hepatic failure, and increased mortality in patients with chronic liver disease.
- Existing data suggest coinfection with HAV and HBV exacerbates liver injury in HCV patients.
Purpose of the Study:
- To review the recommendations and rationale for vaccinating patients with HCV against HAV and HBV.
- To assess the safety and immunogenicity of HAV and HBV vaccines in patients with chronic liver disease.
- To highlight the importance of timely vaccination and the potential benefits of a combination vaccine.
Main Methods:
- Review of current recommendations from health organizations regarding HAV and HBV vaccination in HCV patients.
- Analysis of available data on the clinical outcomes of HAV and HBV superinfections in patients with chronic liver disease.
- Evaluation of the safety and immunogenicity profiles of standard-dose HAV and HBV vaccines in mild-to-moderate liver disease.
- Consideration of emerging data on a combination HAV and HBV vaccine.
Main Results:
- Standard doses of HAV and HBV vaccines are safe and effective in patients with mild-to-moderate HCV or chronic liver disease.
- Vaccination response decreases as liver disease progresses, emphasizing the need for early administration.
- A new combination HAV and HBV vaccine demonstrates comparable safety and efficacy to monovalent vaccines.
Conclusions:
- Routine vaccination against HAV and HBV is recommended for all patients diagnosed with HCV, regardless of disease severity.
- Early vaccination upon HCV diagnosis is critical to maximize vaccine efficacy.
- A combination vaccine offers convenience and may improve compliance among patients with chronic liver disease, warranting targeted healthcare professional outreach.
Abstract:
Individuals with hepatitis C virus (HCV) are at risk for acquiring hepatitis A virus (HAV) or hepatitis B virus (HBV) because of shared risk factors. A number of organizations recommend vaccination against HAV and HBV for patients with HCV. The rationale for vaccinating these patients is to prevent hepatic superinfections. Acute HAV superinfection causes more severe disease, acute hepatic failure, and higher fatality rates in patients with underlying chronic liver disease, specifically chronic HBV infection and chronic HCV infection. Available data, although limited, suggest that HBV coinfection with HAV and HCV causes more severe hepatic injury than infection with HAV or HCV alone. At standard doses, hepatitis A and hepatitis B vaccines are safe and immunogenic in patients with mild-to-moderate hepatitis C or chronic liver disease. Regardless of disease severity, vaccination should be routinely administered to patients upon diagnosis of HCV infection. Early vaccination is important because response to vaccination is reduced as liver disease progresses. Prevaccination and postvaccination serology testing is recommended in specific populations. A new combination hepatitis A and hepatitis B vaccine has been shown to be as safe and effective as monovalent hepatitis A and B vaccines and is currently under review by the United States Food and Drug Administration. A combination vaccine would offer ease of administration and convenience and could increase compliance in patients with hepatitis C or other chronic liver disease: two groups that should be more aggressively targeted by healthcare professionals.
Related Concept Videos
01:17Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:25Hepatitis
01:28Amebiasis
01:28Viral Hepatitis I: Introduction